DGAP-News: PAION AG / Key word(s): Change of Personnel DAVID BERNSTEIN, M.D. JOINS PAION AS MEDICAL ADVISOR & NON EXECUTIVE DIRECTOR OF PAION INC 07.05.2015 / 14:00 --------------------------------------------------------------------- DAVID BERNSTEIN, M.D. JOINS PAION AS MEDICAL ADVISOR & NON EXECUTIVE DIRECTOR OF PAION INC - Dr. Bernstein will support PAION in its effort to bring Remimazolam to the U.S. market - Dr. Bernstein will also provide PAION with strategic insight and work closely with PAION's advisory board of U.S. thought leaders - PAION to be present at the DDW congress (May 17-19, 2015) in Washington, U.S. at booth 1865 Aachen, 07 May 2015 - PAION AG, a Specialty Pharmaceutical Company (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) is pleased to announce today that David Bernstein, M.D. has agreed to become PAION's Medical Advisor. In this role, Dr. Bernstein will participate in building the company's U.S. relationships with the academic community, regulators, associations and industry. He will also play an active role in the growth of the company's value proposition, with a special focus on the U.S. Dr. Bernstein will also be heavily involved in steering PAION's efforts with its recently established medical advisory board, which consists of U.S. national thought leaders in the field of gastroenterology who are also participating in our phase III program. Dr Wolfgang Söhngen, M.D., Ph.D., chief executive officer of PAION AG, said, "I'm thrilled to continue to work with Dr. Bernstein to bring Remimazolam to a commercial success. David's contributions in helping us put together our medical advisory board last year were significant. We hope this will be a long and rewarding relationship with one of the most respected physicians in the field of gastroenterology." Greg Papaz, president and chief executive officer of PAION, Inc., added: "It is a privilege to have a physician of David's prestige as a director of PAION Inc. I am confident he will help us achieve our goals in the U.S." Dr. Bernstein is currently chief of hepatology for both North Shore University Hospital and Long Island Jewish Hospital, as well as the director of the Center for Liver Diseases for the North Shore LIJ Health System and a professor of medicine at the Hofstra North Shore LIJ School of Medicine. Dr. Bernstein has authored over 100 publications, 10 book chapters, and has been the principle investigator in more than 100 clinical trials. His work has been published in such prestigious journals as the New England Journal of Medicine and The Lancet. Dr. Bernstein has held elective offices in many national and international societies. He is the current president of the Bockus International Society of Gastroenterology and a former president of the New York Gastrointestinal Association. He served for six years as the American College of Gastroenterology governor for Long Island and was a member of numerous other medical committees. Currently, he is a fellow of the American Association for the Study of Liver Diseases, the American College of Gastroenterology and the American College of Physicians. He also serves as a special consultant to the New York State Department of Health. He has received numerous awards recognizing his contributions, in academia, as a clinician, and in the field of public health. "I am delighted to be involved with Remimazolam, a welcome alternative for which gastroenterologists have waited many years. I look forward to the challenges ahead and I am confident that we will see the potential of Remimazolam fully realized in the United States," commented Dr. Bernstein. PAION will be present at the Digestive Disease week (DDW 2015) between May 17-19, 2015 in Washington, U.S. and will be available for discussions at booth 1865 in the exhibition hall. About Remimazolam Remimazolam is an innovative ultra-short-acting general sedative/anesthetic. As a result of its short duration of action and good controllability, it has a preferable efficacy and safety profile relative to other currently marketed anesthesia compounds. Remimazolam's rapid offset is a consequence of its metabolism by tissue esterase enzymes that are widely distributed throughout the body. Remimazolam has potential in three indications: - Procedural sedation (Lead indication U.S.) - General anesthesia (Lead indication EU, Japan) - ICU sedation (Phase II Japan) Remimazolam is available for licensing outside China, Russia (CIS) Turkey, MENA Region, South Korea and Canada, where the compound is partnered with Yichang Humanwell, R-Pharm, TR-Pharm, Hana Pharm and Pendopharm. About PAION PAION AG is a publicly-listed Specialty Pharma Company headquartered in Aachen, Germany with further sites in Cambridge, UK and New Jersey, US. The company has a track record of developing hospital-based treatments for which there is substantial unmet medical need. PAION's strategy is to participate in the commercialization of Remimazolam and extend its business with a focus on anesthesia/critical care products. Remimazolam is the building block for its future marketing activities. For more information please visit www.paion.com PAION Contact Ralf Penner Director Investor Relations / Public Relations PAION AG Martinstrasse 10-12 52062 Aachen - Germany Phone: +49 241 4453-152 E-mail: r.penner@paion.com www.paion.com Disclaimer: This release contains certain forward-looking statements concerning the future business of PAION AG. These forward-looking statements contained herein are based on the current expectations, estimates and projections of PAION AG's management as of the date of this release. They are subject to a number of assumptions and involve known and unknown risks, uncertainties and other factors. Should actual conditions differ from the Company's assumptions, actual results and actions may differ materially from any future results and developments expressed or implied by such forward-looking statements. Considering the risks, uncertainties and other factors involved, recipients should not rely unreasonably upon these forward-looking statements. PAION AG has no obligation to periodically update any such forward-looking statements to reflect future events or developments. --------------------------------------------------------------------- 07.05.2015 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: PAION AG Martinstr. 10-12 52062 Aachen Germany Phone: +49 (0)241-4453-0 Fax: +49 (0)241-4453-100 E-mail: info@paion.com Internet: www.paion.com ISIN: DE000A0B65S3 WKN: A0B65S Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 354461 07.05.2015
DGAP-News: DAVID BERNSTEIN, M.D. JOINS PAION AS MEDICAL
Top 10 Most Recent News Articles
Finzly Welcomes Paul Finch to Drive BankOS Growth
Finzly's Strategic Move to Boost Innovation Alright, folks, it seems Finzly means business. They just roped in Paul Finch, the brains who gave us Zelle during his stint as CEO over at Early Warning Services. This guy's been around the block with a couple of the biggest names in banking, and if his past headlines are any indicator, he's got the knack for shaking things up...
Continue Reading
Concierto's Azure Push Puts Sovereignty on Display
Sovereignty has become the corporate cloud world's favorite hard-edged word. Concierto is taking that word straight onto the Microsoft Ignite 2026 floor, and frankly, it is a sensible place to make the case. The company, part of Trianz, will appear as a Gamechanger Sponsor from November 17 through 20 at San Francisco's Moscone Center, showing its platform at Booth #5435....
Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice
A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...
Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves
Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...
Continue Reading
ZTO's Pricing Muscle Shows Up in Third-Quarter Results
Ten billion parcels can hide plenty of ugly economics, but ZTO's third quarter does not look like a volume-at-any-cost stunt. The company moved 10.241 billion parcels, up 7.0% from a year earlier, and says that outpaced the industry by 4.1 percentage points. More importantly, revenue climbed 21.0% to RMB14.36 billion while adjusted net income reached RMB2.57 billion. That...
Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D
Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...
Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious
Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...
Continue Reading
A Decade of Giving: Light the World Initiative's Impact
The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...
Continue Reading
Caracal’s $200K VMI Pledge Targets Cadet Affordability
A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...
Continue Reading
Spruce Spins Adrenyx En Route to Nasdaq in 2027
New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...
Continue ReadingTop 5 Most Recently Viewed Articles
Important Update for Investors in Metagenomi Class Action
Key Deadline for Metagenomi Investors As investors in Metagenomi, Inc. keep a close watch, an important deadline is approaching. The time to file a lead plaintiff motion in the class action lawsuit is set for November 25, 2024. This action is vital for those who purchased or acquired Metagenomi securities, specifically those linked to the company’s latest initial public...
Continue Reading
Structure Therapeutics Engages with Investors at Key Conferences
Structure Therapeutics Engages with Investors at Key Conferences Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company, is gearing up to participate in important investor conferences this September. The company is dedicated to developing innovative oral small molecule therapeutics aimed at treating metabolic and cardiopulmonary...
Continue Reading
OmaSp Reports Solid Financial Performance with Growth Prospects
OmaSp's Strong Financial Performance and Future Outlook OMA SAVINGS BANK PLC has recently released its financial statements for the year ending December 31, 2024, showing promising results and projections for continued growth. Known as OmaSp, the bank reported a noteworthy fourth quarter, aligning with the expectations set forth at the beginning of the year, and a solid...
Continue Reading
Unveiling the Reagan National Economic Forum for Future Growth
Reagan National Economic Forum Set to Inspire Economic Solutions The Ronald Reagan Presidential Foundation and Institute is gearing up for a transformative inaugural economic summit with leading figures from the business and economic policy landscapes to take place in late May 2025. About the Forum’s Objectives The Reagan National Economic Forum (RNEF) aims to provide a...
Continue Reading
Experience the Vibrant Latin Business Networking Event of 2025
Celebrating the Latino Business Community Prepare yourself for an unforgettable networking event dedicated to the Latino business community, brought to you by Latin Biz Today and Mercy University. The Spectrum of Success event promises a night filled with excitement, learning, and cultural experiences that will leave a lasting impression on everyone involved. A Night of...
Continue Reading